BFM
LXEO icon

Boothbay Fund Management’s Lexeo Therapeutics LXEO Stock Holding History

Boothbay Fund Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$635K Hold
136,377
– – 0.01% 1356
2026
Q1 		$783K Hold
136,377
– – 0.01% 1079
2025
Q4 		$1.35M Sell
136,377
-44,367
-25% -$405K 0.02% 697
2025
Q3 		$1.2M Buy
180,744
+17,572
+11% +$85K 0.02% 756
2025
Q2 		$656K Hold
163,172
– – 0.01% 819
2025
Q1 		$566K Buy
163,172
+15,365
+10% +$68.1K 0.01% 812
2024
Q4 		$973K Buy
147,807
+40,323
+38% +$318K 0.02% 647
2024
Q3 		$972K Buy
+107,484
New +$1.28M 0.02% 760

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Boothbay Fund Management's LXEO Position: Q2 2026 in Review

Boothbay Fund Management held its Lexeo Therapeutics (LXEO) position steady in Q2 2026 at 136,377 shares worth $635K. The position accounts for 0.01% of the portfolio, ranked #1356.

Boothbay Fund Management first reported a position in LXEO in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.35M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Boothbay Fund Management held 136,377 shares of Lexeo Therapeutics worth $635K as of Q2 2026.
  • Boothbay Fund Management left its Lexeo Therapeutics share count unchanged in Q2 2026.
  • Lexeo Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1356 holding.
  • Boothbay Fund Management first reported a position in Lexeo Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Boothbay Fund Management's Lexeo Therapeutics position peaked at $1.35M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.